NovaTears® Eye Drops Observational Study NT-002

Novaliq

Status: Completed

Conditions: Dry Eye Syndromes

Treatments: Device: NovaTears® Eye Drops

Study type: Observational

Funder types: Industry

Identifiers

NCT02356341

NT-002

Details and patient eligibility

About

This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.

Enrollment: 72 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• According to NovaTears® instruction for use
• ≥ 18 years
• Patients with dry eye disease due to meibomian gland dysfunction applying eye lid hygiene for at least 14 days
• Ability and willingness to provide written Informed Consent
• Ability and willingness to participate in all examinations
• Willingness and ability to return for follow up visit

Exclusion criteria

• Patients with hypersensitivity to any of the components of NovaTears®
• Patients with contact lenses, pregnancies, or who are breast feeding
• Patients with dry eye disease not caused by meibomian gland dysfunction
• Patients taking lipid containing eye drops or requiring topical pharmacological treatment of dry eye disease

Trial design

72 participants in 1 patient group

NovaTears®

Treatment:

Device: NovaTears® Eye Drops